1,165 results on '"Ketter, Terence A"'
Search Results
202. Definition of the term “mood stabilizer”
203. Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder
204. Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression
205. Regional brain activity during transient self-induced anxiety and anger in healthy adults
206. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders
207. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression
208. GROUP PROCESS IN SHORT-TERM OUTPATIENT THERAPY GROUPS FOR SCHIZOPHRENICS
209. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder
210. Commentary on the Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder
211. Clinical characterization of Italian suicide attempters with bipolar disorder
212. Sensitive and Personalized Determinations of Likelihood of Being Helped or Harmed
213. 901. Abnormal Sleep Duration Associated with Hastened Depressive Recurrence in Bipolar Disorder
214. The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder
215. Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder.
216. Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression.
217. Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder.
218. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial
219. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women
220. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000–2011
221. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder
222. NNT and NNH remain helpful in evidence-based medicine
223. White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder
224. Ketamine: stimulating antidepressant treatment?
225. Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
226. Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes
227. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness)
228. Recognizing the Extent of Overlap Between Bipolar Disorder and Anxiety Disorders
229. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
230. Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients
231. Advancing Stage of Female Reproductive Life Associated with Bipolar Illness Exacerbation
232. Number Needed to Treat Can Be Helpful
233. Why Personalized Treatment Decisions Are Important
234. Assessing Cognitive Function in Bipolar Disorder: Challenges and Recommendations for Clinical Trial Design
235. Psychotherapy use in bipolar disorder: Association with functioning and illness severity
236. Complexity of Illness and Adjunctive Benzodiazepine Use in Outpatients With Bipolar I or II Disorder
237. Bipolar Therapeutics Update 2014: A Tale of 3 Treatments
238. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium
239. Advances in the diagnosis and treatment of bipolar depression
240. Distinguishing Bipolar Disorder From Other Psychiatric Disorders in Children
241. Corrigendum to “Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the bipolar CHOICE trial” [J. Affect. Disord. 161 (2014) 30–35]
242. Differential abnormalities of functional connectivity of the amygdala and hippocampus in unipolar and bipolar affective disorders
243. Sleep matters: Sleep functioning and course of illness in bipolar disorder
244. Lifetime eating disorder comorbidity associated with delayed depressive recovery in bipolar disorder.
245. Lifetime presence of psychotic symptoms in bipolar disorder is associated with less favorable socio-demographic and certain clinical features.
246. White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder.
247. Poor quality of life and functioning in bipolar disorder.
248. Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder.
249. American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence.
250. Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.